Search results
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). [1] There is some evidence it may improve some ME/CFS symptoms.
Additionally, Ampligen is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post-COVID Conditions.
4 kwi 2023 · AMP-518 is expected to enroll approximately 80 subjects between the ages of 18 to 60 years across up to 10 centers in the United States. Patients will be randomized 1:1 to receive twice weekly...
9 lut 2015 · Ampligen (rintatolimod) is a new drug in development for the treatment of a variety of chronic diseases and viral disorders. Ampligen information includes news, clinical trial results and side effects.
Ampligen (Rintatolimod) is the trade name for a very expensive American drug (produced by AIM Immunotech) that is claimed to have both antiviral and immuno-modulatory properties. Benefits have been reported by a number of clinicians (mainly in America) who use this drug in selected ME/CFS patients.
11 lis 2022 · In October 2022, an immuno-pharma company known as AIM ImmunoTech received approval from the FDA to start its Phase 2 study to evaluate their Investigational New Drug (IND), Ampligen, as a potential treatment for long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
25 sty 2024 · AIM ImmunoTech has gained Netherlands Erasmus Medical Center (Erasmus MC) Ethics Committee authorisation to launch a European site for its Phase II clinical trial of Ampligen (rintatolimod) for locally advanced pancreatic cancer.
